Acute eosinophilic pneumonia related to a mesalazine suppository

Kim, Jung Hyun; Lee, June-Hyuk; Koh, Eun Suk; Park, Sung Woo; Jang, An‐Soo; Kim, Dojin; Park, Choon-Sik

doi:10.5415/apallergy.2013.3.2.136

Cited by 26 publications

(22 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5a). Yet, several clinical studies showed the potential pulmonary toxicities (including pneumonia) associated with mesalazine usage 81,82 . Integration of lung-specific gene expression 23 of 2019-nCoV/SARS-CoV-2 host proteins and physiologically based pharmacokinetic modeling 83 may reduce side effects of repurposable drugs or drug combinations.…”

Section: Discussionmentioning

confidence: 99%

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

et al. 2020

View full text Add to dashboard Cite

Human coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV) and 2019 novel coronavirus (2019-nCoV, also known as SARS-CoV-2), lead global epidemics with high morbidity and mortality. However, there are currently no effective drugs targeting 2019-nCoV/SARS-CoV-2. Drug repurposing, representing as an effective drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV-host interactome and drug targets in the human protein-protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Using network proximity analyses of drug targets and HCoV-host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines. We further identify three potential drug combinations (e.g., sirolimus plus dactinomycin, mercaptopurine plus melatonin, and toremifene plus emodin) captured by the "Complementary Exposure" pattern: the targets of the drugs both hit the HCoV-host subnetwork, but target separate neighborhoods in the human interactome network. In summary, this study offers powerful network-based methodologies for rapid identification of candidate repurposable drugs and potential drug combinations targeting 2019-nCoV/SARS-CoV-2.

show abstract

Section: Discussionmentioning

confidence: 99%

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Regarding adverse events due to mesalazine, certain pulmonary toxicities have already been reported (5,6,25). Notably, two previous reports have described OB in patients with UC receiving mesalazine (6,7), as observed in the present case; however, the cause and precise mechanism of OB resulting from mesalazine treatment is not currently known.…”

Section: Discussionmentioning

confidence: 49%

Severe airflow obstruction in a patient with ulcerative colitis and toxic epidermal necrolysis: A case report

Taguchi

Furuta

Ohara

et al. 2015

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Bronchiolitis is a rare condition mainly affecting the intralobular conducting and transitional small airways. The present study describes a case of severe airflow limitation in a patient with ulcerative colitis who developed toxic epidermal necrolysis following mesalazine therapy. Forced expiratory volume in one second was decreased and a flow-volume curve showed airflow limitation, but the single-breath diffusing capacity of the lung for carbon monoxide (DL CO ) and DL CO divided by alveolar volume (DL CO /VA) were not decreased. This rare clinical condition should be considered as a differential diagnosis for subjects presenting with sub-acutely developed airflow obstruction if the findings in chest computed tomography scans demonstrate hyperinflation but few low-attenuation areas. Relatively well-preserved DL CO and DL CO /VA provide a clue to establishing the correct diagnosis.

show abstract

“…Steroid tedavi iyileşmeyi hızlandırmak-tadır. [1][2][3][4][5][6] Mesalazin bronşiyal obliterans organize pnö-moni, nonspesifik interstisyel pnömoni, eozinofilik pnömoni gibi interstisyel akciğer hastalıklarına neden olabilmektedir. 3 Mesalazine bağlı akciğer hasarının mekanizması net olarak belli değildir.…”

Section: Discussionunclassified

“…Tanı; çoğu hastada BAL'da eozinofili saptanması ve transbronşiyal akciğer biyopsisinde eozinofilik pnömoniyi destekler bulgularla koyulmaktadır. [1][2][3][4][5][6] Patolojik tablo diğer pulmoner hastalıklarla örtüşebilmesine rağmen biyopsi örneklerinde kronik interstisyel pnömoni bulguları yanında zayıf forme nonnekrotizan granülomların varlığı bu ilacı kullanan hastalarda ilaca bağlı reaksiyonları düşündürmelidir. 5 İlaca bağlı akciğer hasarının bulguları, inflamatuar barsak hastalığına bağlı bulgulara çok benzediği için tanı koymak güç olabilmektedir.…”

Section: Discussionunclassified